The recommendations are learnt to have been approved by the DCGI. In August 2020, US-based vaccine maker Novavax Inc. had announced a licence agreement with the SII for the development and commercialisation of NVX-CoV2373, its COVID-19 vaccine candidate, in low and middle-income countries and India.Latest News of India, Sports, Tech, Technology 2021 from Top India News- News18.com for more info CLICK HERE
0 Comments